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Abstract 
Sickle cell pain includes three types: acute recurrent painful crises, chronic pain syndromes and 
neuropathic pain. The acute painful crisis is the hallmark of the disease and the most common 
cause of hospitalization and treatment in the Emergency Department. It evolves along four 
phases: prodromal, initial, established and resolving phases. Each acute painful episode is 
associated with inflammation that worsens with recurrent episodes and often culminates in 
serious complications and organ damage such as acute chest syndrome, multiorgan failure and 
sudden death.  Aborting the acute painful episode at the prodromal phase could potentially 
prevent or minimize tissue damage. Three pathophysiologic events operate in unison at the 
prodormal phase of the crisis: Vaso-occlusion, inflammation and nociception. Managing these 
events with vasodilators, anti-inflammatory drugs and aggressive analgesia could abort the crisis 
and prevent or minimize further damage. Chronic pain syndromes include avascular necrosis and 
leg ulcers.  Neuropathic pain is usually due to nerve damage following vaso-occlusion of blood 
vessels (vasa vasorum) feeding nerves. Management of sickle cell pain should be based on its 
own pathophysiologic mechanisms rather than borrowing guidelines from other non-sickle pain 
syndromes. 
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Introduction 
 
The proper study of mankind is Man. 
     Alexander Pope 
 
 
Sickle cell disease (SCD) has been considered primarily a disease of children with a few patients 
surviving to adulthood. Thus, between 1910 and 1950 the median survival of patients with SCD 
was less than 20 years of age 1 and sudden death occurred in about 41% of the patients and in 
29% death occurred within 24 hours after the onset of painful crises2.  By 1980 50% of children 
survived to 20 years of age and by 2009 survival to age 20 years increased to 85% of children 2. 
If we rewind the clock of time by five scores and two years when SCD was first discovered in 
the US, however, we find that the first four patients were adults, not children and they all had leg 
ulcers3-6 . Even before 1910 there were observations among adult African slaves suggestive of 
sickle cell disease. These included immunity to malaria and high prevalence of leg ulcers 7. 
Moreover autopsy on a slave with history of fever and respiratory illness in 1846 showed 
absence of the spleen 8.   The inevitable question then, is where were the children with SCD in 
the US before 1910? There must have been children with SCD. The patient reported by Cook 
and Meyer 5 gave family history of brothers and sisters who died in early life of a disease 
associated with grave anemia. Only our imagination describes the pain and suffering that 
affected infants and children with SCD. These innocent souls must have lived, suffered and died 
prematurely, invisible and hidden within the shrouds of the dark side of the discovery of sickle 
cell anemia in the US9. It was not until the early 1930’s that children with SCD were recognized 
as the major victims of this disease.  
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Sickle Cell Pain between 1930 and 1960 
Between 1930 and 1960 the emphasis was on studying the basic science of SCD. This period 
witnessed quantum leaps in defining the specific molecular lesion of SCD and the advent of Hb 
electrophoresis10-12. Diggs and Ching 13 suggested that the painful sickle cell crises are the result 
of blockage of the small blood vessels by the abnormal red cells. The major therapeutic approach 
was to identify methods to prevent the blockage of small blood vessels by the sickled cells. Not 
much was written about specific pain management during this period partly because of the pre-
occupation with the basics and partly because potent analgesics were not available then.  
Nevertheless Diggs realized that pain was a major problem among patients with sickle cell 
anemia (SS) and used papaverine and acetaminophen to treat it 14. Other futile therapeutic 
modalities included liver extract, whole liver diet, spleen diet, iron, arsenic, calcium, iodides, 
alkalis, blood transfusion, urea, cyanate and hyperbaric oxygen15-19.  
We reviewed 398 charts of the patients seen by Diggs and Kraus at the University of Tennessee 
in Memphis. There were descriptions of severe anemia, leg ulcers, skeletal abnormalities, death, 
etc and pain. It seems the physicians were at loss how to treat the pain. They used whatever they 
thought might help including most of the methods mentioned above and enemas for patients with 
abdominal pain. Papaverine, a naturally occurring opioid derived from the opium puppy known 
for its anti-spasmodic effect, was the ideal analgesic for abdominal painful crises. What is most 
admirable about Diggs and Kraus is that they believed their patients and listened to them with 
great empathy and respect. 
In the 1960’s adult patients with SCD appeared on the scene again; but this time with severe pain 
that often did not respond to oral analgesics. Patients had to resort to the Emergency 
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Departments (ED) for help. At that time the only parenteral opioids approved by the FDA for 
pain management were meperidine (approved in 1942) and fentanyl citrate (approved in 1968).  
The latter, however, was approved for surgical use only and meperidine became the drug of 
choice to treat severe sickle cell pain. Follow-up studies of the Multicenter Study of 
Hydroxyurea (MSH) in SS showed that meperidine was most often used for painful crises in the 
ED and Hospital and short-acting oxycodone with acetaminophens most often used for pain at 
home.20, 21   
 
Sickle Cell Pain and Opioids: Is Morphine the Ideal and only Opioid for 
Sickle Cell Pain? 
A shift in the management of sickle cell pain from meperidine to morphine occurred in the 
1990’s. Morphine sulfate was approved by the FDA in 1984 and was widely used in the 
management of cancer pain. Brookoff and Polomano22 published a paper titled “Treating Sickle 
Cell Pain like Cancer Pain”. This initiated a trend to treat sickle cell pain by borrowing methods 
from other disciplines rather than establish treatment based on the specific pathophysiology of 
the disease itself. Brookoff and Polomano 22 reported that using intravenous and controlled 
release oral morphine instead of meperidine reduced the frequency of hospital admissions of 
patients with painful crises and their length of stay. It turned out, however, that the decrease was 
probably because many of their patients transferred their care to other hospitals in the area after 
the institution of the morphine-only policy 23. Unfortunately, this policy gave the wrong message 
to providers who thought that morphine is the only opioid to be used to treat acute painful crises. 
An ultimatum was created for the patients: “you will be treated with morphine or you go 
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somewhere else”, where the somewhere else often used the same ultimatum. Tragedies occurred. 
One patient told her provider she is allergic to morphine. This was not taken seriously and she 
was given morphine intravenously anyway. Within minutes she had an anaphylactic shock but 
luckily she could be managed successfully in the intensive care unit (Ballas, Unpublished data).  
The meperidine phobia emerged because normeperidine, the major metabolite of meperidine is 
neurotoxic and may cause seizures especially in patients with impaired renal function. There are 
no controlled trials to compare meperidine with morphine in patients with sickle cell disease. 
The incidence of seizures related to the use of meperidine in patients with SCD varies between 
1% and 12%24-26. There are a few patients to date for whom meperidine is the ideal analgesic for 
the acute painful crisis with no evidence of neurological complications. 
Although there are no controlled trials to compare the safety and efficacy of different opioids in 
the management of acute sickle cell crises, patient safety can be maximized by obtaining a 
detailed history, understanding opioid pharmacology & their mechanism of action & side effects, 
carefully monitoring patients and individualizing care. Meperidine should not be used to treat 
acute sickle cell pain in patients who have impaired renal function, history of seizure disorder, or 
who are taking serotoninergic medications.  A sickle cell center that uses only one opioid to treat 
all patients with SCD all the time raises questions about the justifications and rational for such a 
restricted policy. 
Ironically it turned out that morphine is not a panacea after all. Like other medications it carries a 
load of problems associated with its use. Morphine also causes seizures with a reported 
prevalence of 1.2% if given in sufficiently large doses 27. Morphine is the most histaminergic 
opioid 28 and is often associated with severe pruritus in some patients. Moreover, there have been 
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reports of death with the use of morphine in patients with sickle cell disease29, 30. The use of 
morphine in patients with SCD seems to be associated with acute chest syndrome31-33. In 
addition morphine and morphine-6-glucoronide, a major metabolite of morphine, are both 
excreted in the urine and care has to be taken if given to patients with renal failure.  Morphine 
induces expression of platelet derived growth factor-b (PDGF-BB) in human brain and umbilical 
vein endothelial cells 34, 35.  Morphine also activates VEGFR2, PDGFR-b, SIP3R, MAPK/ERK 
and COX-2 in endothelial cells and the central nervous system 35-39. Together, these growth 
factor-like activities of morphine stimulate vascular permeability, endothelial activation, vascular 
smooth muscle cell pathology, analgesic tolerance and kidney disease. Morphine induces kidney 
injury in transgenic sickle mice40.  Studies in the transgenic sickle mouse showed that morphine 
amplifies renal pathology, stimulates albuminuria and impairs renal function. Morphine 
stimulates the proliferation of glomerular, mesangial and epithelial cells, but causes apoptosis at 
higher concentration, representing early and late lesions36, 41, 42. Thus morphine may contribute to 
both development and progression of renal lesions in SCD.  These morphine-induced signaling 
mechanisms also support clinical observations of pulmonary edema in patients receiving 
morphine and hydrated or over-hydrated at the same time. Increased vascular permeability 
induced by morphine may be associated with hemorrhagic stroke in SCD. Considering the 
endothelial-specific effects of morphine, mechanism(s) of morphine signaling need to be 
critically evaluated for their contribution to organ disease while treating patients with SCD. 
 
At the present several opioids are available for parenteral use as needed including morphine, 
codeine, meperidine, hydromorphone, oxymorphone, levorphanol, methadone, and fentanyl. The 
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choice of opioid, its dose and route of administration has to be individualized with frequent 
monitoring for possible side effects and to minimize risks of abuse, misuse or diversion. 
 
 
The Acute Sickle Cell Painful Crisis 
The acute sickle cell painful crisis is the hallmark of SCD and the number-one cause of 
hospitalization 43.  It is unpredictable  and may be precipitated by known or unknown risk factors 
and triggers 44. Much of the devastation caused by the disease is due to the recurrent acute 
painful crises. Diggs45 described the clinical features of a typical painful crisis accurately. He 
reported that “patients experience sudden onset of pain in the low back or in one or more joints 
or ones of the extremities. The pain may be localized or migratory and is continuous and 
throbbing. The severe pain causes patients to grunt, groan, cry, twist and turn and to assume 
abnormal postures in the futile attempt to obtain relief”. Descriptors of pain include, among other 
things, throbbing, sharp, pounding, dull, stabbing, cutting, and gnawing or like a generalized 
toothache44. 
Extensive review of the literature pertinent to the clinical description of the painful crisis 
requiring hospitalization showed that it evolves along distinct phases. Ballas and Smith46 and 
Akinola et al47 independently and almost simultaneously described the presence of two phases of 
the uncomplicated painful crisis in prospective longitudinal studies of adults with SCD.  Akinola 
et al47 studied 20 patients over 16 months, and Ballas and Smith46 studied 117 painful crises 
affecting 36 patients with sickle cell anemia over 6 years. Both studies indicated the presence of 
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two phases. The initial phase was associated with increasing pain, decreased RBC deformability, 
increase in the number of dense cells, red cell distribution width (RDW), hemoglobin 
distribution width (HDW), reticulocyte count, leukocytosis and relative thrombocytopenia. The 
second phase was characterized by established pain of maximum severity and gradual reversal of 
the abnormalities of the first phase. Later, Ballas48 revised the description of the painful crisis 
and refined its evolution into four phases by including observation by several other investigators. 
For example Murray & May49 reported a premonition of painful crisis in 59 out of 102 
(58%patients with SCD) during a questionnaire study in the UK. Reported symptoms included 
numbness, parasthesia or aches in the areas that subsequently became painful. The duration of 
the prodromal phase was up to one or two days. The phases were called prodromal, initial, 
established, and resolving phases (Figure 1). Beyer et al50 and Jacob et al 51 reported the 
evolution of painful crises along similar phases in children.  
The presence of phases of the crises allows providers to monitor the progress of the crisis and 
manage it according to rational basis and avoid the conflicts that often arise about the 
authenticity of pain. As shown in Fig 1 and Table1 a number of changes in objective signs occur 
during the evolution of the crisis. These changes, however, can be appreciated if the parameters 
are determined serially and, more importantly, if they are compared to steady state values 52. The 
decrease in Hb level and the increase in the reticulocyte count, for example, suggest 
hyperhemolysis that occurs in some patients during uncomplicated painful crises 53. 
 
Consequences of the acute painful crisis 
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The acute painful crisis is associated with serious complications of the disease. About 50% of 
reported cases of acute chest syndrome occur after admission to the hospital with a painful 
crisis54. Acute multiorgan failure 55 and sudden death56 also have been reported during painful 
crises. Most of these serious complications usually occur during day 1-5 of the crisis. 
As shown in Fig 1 and Table 1 the resolution of the painful crisis is associated with rebound 
thrombocytosis, elevated levels of fibrinogen, orosmomucoid, RBC deformability and plasma 
viscosity indicating the presence of a hypercoagulable state that may cause recurrence of the 
crisis. Ballas and Smith 46 found that about 20% of the patients who were discharged from the 
hospital after the resolution of a crisis had recurrent crises that required treatment with parenteral 
opioids in the ED or hospital within one week after discharge (Table 2). A painful crisis seems to 
be a risk factor to precipitate another crisis. Some patients, especially children, however, do well 
after the resolution of a crisis with a pain-free-period of variable duration before the onset of 
another crisis (Fig2). Others continue to have pain. According to the Pain In Sickle Cell 
Epidemiology Study (PISCES) adult patients reported SCD pain at home in about 55% of the 
31,017 days surveyed57. Similarly children reported SCD pain at home on about 9% of the1515 
days surveyed58, 59.  In MSH at-home analgesics were used for SCD pain on 40% of diary days 
and 80% of two-week follow-up periods, with short-acting oxycodone and acetaminophen  being 
the most frequently used analgesics 21, 60. Descriptors and location of the pain at home ware 
similar to those during hospitalization but milder. What is important about the pain experienced 
at home is that patients prefer to treat it with short-acting opioids rather than the controlled-
release opioids. Moreover, those who take controlled release opioids with short acting opioids 
for breakthrough pain experience frequent attacks of breakthrough pain resulting in the 
consumption of relatively large amounts of short-acting opioids. In addition, patients prefer to be 
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treated in the day unit rather than the ED whenever possible in order to avoid long hours of 
waiting before they are treated. Treatment of patients in the day unit with parenteral short-acting 
opioids decreased the frequency of hospital admissions and ED visits61.  
 
In order to determine the actual pattern of hospital admissions of patients with SS and the causes 
of frequent hospital readmissions and their prognostic significance a prospective longitudinal and 
observation cohort study of all adult patients with sickle cell anemia admitted to one institution 
between January 1998 and December 2002 was conducted43.  Major outcome measures included 
the frequency, etiology, and prognostic significance of readmissions to the hospital within 1 
week and 1 month after discharge. Analysis of the data showed the following: 1) about 95% of 
all the 1540 admissions of 136 patients were for acute painful crises; 2) the intensity of pain 
score decreased significantly during the first 4 days of hospital admission from an average of 8.7 
±1.17 to 7.5 ± 1.00 (P < 0.001) and then reached a plateau of 7.4 until discharge. (Fig. 3); 3) the 
mean score of pain intensity was >7 throughout the hospital stay; 4) about 50% of hospital 
admissions for acute painful episodes were readmitted within 1 month after discharge, and about 
16% of all admissions were readmitted within 1 week after discharge (Table 3). The major cause 
of hospital readmission was the same acute sickle cell pain  that was not controlled with 
analgesics at home or in the ED. Withdrawal syndrome was the cause of readmission only in five 
patients who were readmitted collectively 46 times (about 7% of all readmissions) within one 
week after discharge. Readmission within 1 week after discharge was associated with higher 
mortality than otherwise.43 
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 Jacob et al 62 showed similar pattern of pain score that plateaus about 5 days after hospital 
admission for painful crises in children. Moreover, the high frequency of hospital readmission 
was confirmed by other studies63-65.  In a Retrospective cohort of sickle cell disease–related ED 
visits and hospitalizations from 8 states (Arizona, California, Florida, Massachusetts, Missouri, 
New York, South Carolina, and Tennessee) in the 2005 and 2006 Healthcare Cost and Utilization 
Project (HCUP) State Inpatient Databases and State Emergency Department Databases, 
Brousseau et al63 found that the 30-day and 14-day readmission rates were 33.4% and 22.1% 
respectively. Readmissions were highest for the 18- to 30-year old patients and for the publicly 
insured patients. In another retrospective study in children with SCD, the most common 
admission and readmission (within 30 days) diagnosis was acute pain, 78 and 70% respectively64 
. The major risk factor for readmission was lack of outpatient hematology follow-up within 30 
days after discharge; Asthma was another risk factor for readmission within 30 days. Sobota et 
al65 performed a retrospective examination of 12,104 hospitalizations for sickle cell crisis from 
July 1, 2006 and December 31, 2008 at 33 freestanding children’s hospitals in the Pediatric 
Health Information System (PHIS) database. They identified 4,762 patients with 12,104 
qualifying hospitalizations of which 2,074 hospitalizations (17%) were readmissions for sickle 
cell crisis within 30 days after discharge. Risk factors for readmission included older children, 
pain and treatment with steroids.   
Available data about the evolution of the sickle cell painful crisis show that about 10% of 
children and about 50% of adults with sickle cell disease continue to have pain between painful 
episodes. The severity of the pain between crises varies among individuals and in the same 
individual with time. Thus the hallmark of sickle cell disease seems to be continuous acute pain 
the severity of which varies from severe to mild or moderate. When the pain is severe it requires 
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treatment in the ED or in the hospital with parenteral opioids and when it is mild or moderate it 
is treated at home with oral analgesics. The transition from acute painful crises with no pain in 
between to acute painful crises with mild or moderate pain in between is age dependent. Thus the 
majority of children are pain free between recurrent painful episodes (Fig 2) and about 50% of 
adult continue to have mild to moderate pain between relapsing crises (Fig 4). The descriptors of 
the pain are mostly the same and short acting opioids are the preferred analgesics by the majority 
of adult patients.  
 
 
 
Pathophysiology of acute pain 
Vaso-occlusion is the most important pathophysiologic event in sickle cell disease that explains 
most of its clinical manifestations. Tissue damage due to vaso-occlusion initiates complex 
biochemical, neurological, electrochemical and inflammatory sequence of events collectively 
referred to as nociception that culminates in the perception of acute pain. It is the combination of 
ischemic tissue damage and secondary inflammatory response that makes the pain of sickle cell 
disease unique in its acuteness and severity (Fig 5). Tissue injury generates several pain 
mediators66-69 that bind to and activate or sensitize specific receptors at the peripheral nerve 
ending where biochemical energy is transformed into electrical energy that facilitates the 
transmission of the electric impulse of pain along peripheral nerves to the dorsal horn of the 
spinal cord via the dorsal root ganglion. Each neuron has multiple receptors and the more 
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receptors activated the faster and the more intense the transmission of the painful impulse would 
be. From the dorsal horn of the spinal cord the electrical impulse of pain ascends along the 
contralateral spinothalamic tract to the thalamus that interconnects reversibly with other centers , 
most notably the limbic system (mediator of memory  and emotion) and the reward system 
(mediator of pleasure and addiction). The pathway of pain stimuli is subject not only to 
activators, sensitizers and facilitators, but also to inhibitors. Serotonin, norepinephrine, 
enkephalin, β-endorphin and dynorphin are endogenous central pain inhibitors. Thus, in a given 
patient, the net outcome of tissue ischemia may be severe or mild pain, depending on the extent 
of tissue damage and the net balance of pain stimulators versus pain inhibitors. This may explain, 
in part, the considerable variation in the frequency and severity of painful sickle crises among 
patients, and longitudinally in the same patient. Moreover, psychological, social, cultural and 
spiritual factors often unite and conspire with vaso-occlusion to initiate the unique nature of 
sickle cell pain. 
Central Sensitization and Neuroplasticity 
Painful stimuli that originate peripherally are subject to modification once they reach the central 
nervous system both at the level of the spinal cord and the brain. This modification depends on 
the nature and frequency of transmission of the painful impulse. Repetitive and severe painful 
impulses from the periphery cause changes in excitability of the neurons in the spinal cord. This 
increase in neuronal excitability in the spinal cord is termed central sensitization70, 71. It explains 
the persistence of pain at the primary site of tissue damage and its spread to sites beyond the 
primary site of tissue damage.  Another type of modification of the repetitive and severe painful 
impulse occurs at the level of the brain72, 73.  The main function of the brain is message 
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transmission. To do this, it has 100 billion neurons and each neuron connects to 10,000 other 
neurons via synapses resulting in one million billion connections74. Thus the severe and 
repetitive pain impulse that reaches the brain will excite an enormous number of neurons that 
stimulate other neurons in a progressive manner resulting in the perception of severe pain. 
Neuroscientists describe this mass transit of information as “cells that fire together wire 
together"74.  Moreover, the brain is neuroplastic; it has the ability to change functionally in 
response to experiences74.  This is often referred to as “Rewiring” of the brain of patients who 
have persistent severe pain. Alternative circuits of pain transmission and remapping of functional 
connections74 occur in the brains of these patients. The best example of this phenomenon in 
patients with SCD is that severe pain persisted for several weeks or months in those patients who 
were cured from sickle cell after successful bone marrow transplantation 75.  It took relatively 
long time to reset the “wiring” of the brain back to normal in these patients. 
 
Chronic Pain 
Chronic pain is pain that does not go away. It is often defined as pain that persists for 3 or more 
months. Sources of chronic pain in sickle cell disease include bone infarction, avascular necrosis 
of joints, back pain from disk protrusion into vertebral bodies, leg ulcers, and chronic 
osteomyelitis.76 The descriptors of the pain of these conditions are different from the pain 
associated with the acute painful crisis or the pain that persists between crises. The pain of these 
syndromes is usually treated with long-acting or control-release opioids and short-acting opioids 
for breakthrough pain are not used as often as is the case in the persistent pain between acute 
painful crises.77 Moreover, these pain syndromes rarely require hospital admission except when a 
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painful crisis is superimposed on the chronic pain or if the underlying condition is associated 
with severe infection that requires parenteral antibiotics as may happen in leg ulcers.   
We and others previously described a second type of chronic pain in SCD.76, 78-80  It is intractable 
chronic pain without obvious pathology where the only complaint is the patient’s self-report of 
pain that does not go away. I think we were adopting and borrowing concepts from other pain 
disciplines. We need to reconsider this. SCD does have obvious pathology documented by the 
presence of the sickle gene and sickle Hb which are pathologic. It seems we were referring to the 
persistent pain between crises as chronic pain without pathology.  
 
Neuropathic pain 
Neuropathic Pain is usually described as numb, tingling, lancinating, spontaneous, shooting or 
paroxysmal in nature associated with a sensation of pins and needles, hyperalgesia and allodynia 
(pain due to ambient non-noxious stimuli).76, 79  Its severity is also enhanced by exposure to 
either cold or heat.  This pain could be secondary to nerve injury or nerve dysfunction whether 
peripherally or centrally. Neuropathic pain in SCD could be due to tissue damage following 
vaso-occlusion of blood vessels of nerves (vasa vasorum). These include mental nerve 
neuropathy,81, 82 trigeminal neuralgia83, acute proximal median mononeuropathy84,  entrapment 
neuropathy 85 acute demyelinating polyneuropathy 85, ischemic optic neuropathy86, orbital 
infarction87, orbital apex syndrome88, and spinal cord infarction.89 Neuropathic pain that is often 
associated with persistent acute or chronic pain has not been well studies in SCD to date. 
 Redefining Sickle Cell Pain  
 18 
 
 
We wish to paraphrase Alexander Pope's quotation by saying: “the proper study of sickle cell 
pain is patients with SCD". Although the molecular pathophysiology of SCD is well understood, 
the management of sickle cell pain, its hallmark, is an embarrassing failure. Neglect, disparity, 
prejudice, disinterest and faulty assumptions & accusations punctuate the treatment of patients, 
especially adults, with sickle cell pain. Our perspectives redefine sickle cell pain and its unique 
features based on available data and the experience of experts in the field that accumulated since 
1910. This redefinition may reveal new avenues to improve our understanding and management 
of this complex pain syndrome. Our knowledge of sickle cell pain that evolved over the last 102 
years suggests that the hallmark of SCD is acute pain that waxes and wanes, relapses and remits 
in a recurrent and unpredictable fashion. When severe it is the acute painful crisis that requires 
treatment with parenteral analgesics in the ED or Hospital. When mild or moderated it is the 
residual or persistent acute pain between two subsequent acute painful episodes. This explains 
why patients are often readmitted after discharge, why they prefer using short-acting analgesics 
and why they are treated in the day unit frequently with short acting opioids between hospital 
admissions. It is tempting to call the persistent pain between two crises “chronic acute pain”, but 
such terminology is confusing and it is better to use the persistent or residual nomenclature. The 
use of “chronic sickle cell pain” should be limited to the chronic pain syndromes mentioned 
above. 
The emerging picture of the acute sickle cell pain is that early in life the pain is episodic with 
periods of acute pain alternating with pain free intervals in between (Fig. 2) but as they age mild 
or moderate acute pain persists between episodes of painful crises (Fig, 4) The severity of the 
residual pain between crises varies in intensity among patients and in the same patient with time. 
The pattern of pain shown in Fig 4 occurs in about 50% of adult patients with SCD.21, 57, 60 
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New Approach to Therapy 
Aegeus Euripides (484 BC-404 BC) said: “A bad beginning makes a bad ending”. Thus if the 
acute painful crisis is treated aggressively at its beginning, its end would be of short duration 
with little or no complications. Unfortunately, the end of an acute sickle cell painful crisis at the 
present is a fuzzy point in time. Discharge from the ED or Hospital does not necessarily indicate 
the end of the crisis. It is an arbitrary point that depends on several factors that are not based on 
the individual status of the patient but subscribes to insurance coverage, Hospital policy and the 
attitude of the providers. Table 4 lists the approaches for the treatment of SCD and its 
complications. The ultimate goal is to achieve a cure. Short of that preventing the painful crisis 
with agents that induce the production of Hb F is possible and short of that aborting the painful 
crisis is highly desirable. A triad of pathophysiologic factors initiates the acute painful crisis: 
vaso-occlusion, inflammation and nociception.  Each painful crisis is associated with residual 
inflammatory damage that accumulates with recurrent crises culminating in organ dysfunction 
and organ failure. The rational approach to abort a crisis is to treat it early at the prodromal phase 
where tissue ischemia and inflammation are in their early stages 90 (Fig 5).  The goal of 
management at this phase is anti-vasocclusive therapy akin to therapy of ischemic stroke in 
adults in the general population91, 92  and to the treatment of acute myocardial infarction (MI)93, 
94
. The standard of care of ischemic stroke and MI is to give tPA within a few hours after the 
onset of signs and symptoms in order to restore perfusion. Beyond that tPA will not be as 
effective. Anti-vasoocclusive therapy to abort a crisis at the prodromal stage should include 
vasodilatores, anti-inflammatories and analgesics. Diabetics determine their blood glucose level 
at home and treat themselves with antiglycemic agents accordingly. Patients with SCD could be 
counseled and trained to treat themselves at home as soon as they feel an impending crisis. Nitric 
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oxide would be the ideal vasodilator for self-administration at home. Gladwin et al showed that 
NO in the hospital is not effective in reducing the hospital length of stay of patients with painful 
crises.95 Administration of NO in the ED, however, was effective in aborting crisis in some 
patients.96, 97 It is probable that shifting the utilization of NO to the left (at home) rather than to 
the right (Hospital) is the right way to go. Moreover blood transfusion or vigorous hydration at 
the prodromal phase may be effective in aborting the crisis. Sobota et al  reported that transfused 
pediatric patients with crisis were readmitted less frequently to the hospital than otherwise.65 The 
combination of NO and blood transfusion/hydration  in the prodromal phase would restore 
perfusion and prevent or minimize damage due to hypoxia,  the addition of anti-inflammatories 
would prevent or minimize damage due to inflammation and, most importantly, aggressive 
management of pain would prevent the barrage of painful impulses from reaching the brain thus 
avoiding its “rewiring”. 
According to the current state of affairs patients with acute painful crisis receive treatment about 
2-3 days after the onset of the early prodromal signs and symptoms of the crisis. By that time 
irreversible tissue damage is well established and difficult to reverse. This has to change. The 
rational therapy of acute sickle cell pain must be actively based on its own mechanistic 
pathophysiology and not by the passive adoption of guidelines of other pain syndromes. 
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Table 1. Changes in objective signs during the evolution of the sickle cell painful crisis 
Podromal Phase   Initial Phase       Established Phase        Resolving Phase 
Decreasing  Decreasing  Peak    Peak 
RBC deformability RBC deformability Temperature   Fibrinogen 
   Platelets  WBC count   Orosomucoid 
Increasing     Dense Cells   ESR 
Dense RBC  Increasing  ISC       
  Temperature  RDW    Decreasing 
   WBC count  HDW    Temperature 
   Dense cells  Reticuloytes   WBC Count 
   ISC   LDH    Dense Cells 
   RDW   CRP    ISC 
   HDW   SAA    RDW 
   ESR       HDW 
   LDH   Nadir    CRP 
   CRP   RBC deformability  
   Fibrinogen  Hb    Increasing 
   Orosomucoid                RBC deformability 
   SAA   Increasing              Plasma viscosity 
      Fibrinogen   Platelets 
      Orosomucoid 
      Plasma viscosity 
      ESR 
Note: Parameters shown are those reported at least twice by different investigators. ISC, 
irreversibly sickled cells; WBC, white blood cells; RDW, red cell distribution width; HDW, 
hemoglobin distribution width; ESR, erythrocyte sedimentation rate; LDH, lactate 
dehydrogenase; CRP, C-reactive protein; SAA, serum amyloid A; Hb, hemoglobin.  
From Ballas SK. Sickle Cell Pain 44. Progress in Pain Research and Management, Vol.11; 
 Seattle, WA, IASP Press, 1998; with permission 
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                    Table 2 Incidence of Recurrent Painful crises (1985-1989) 
 
 
            Year 
 
 
 
Admissions* 
          n 
Recurrent Crises After Discharge† 
 
Within 1 wk              Within 1 mon 
         n (%)                         n (%) 
          1985          209        31(14.8)                 127(60.8) 
          1986          266        73(27.4)                 155(58.3) 
          1987          246        67(27.2)                 157(63.8) 
          1988          307        61(20.0)                 154(50.2) 
          1989          427        59(13.5)                 214(50.0) 
 
Total  
 
       1465 
     
   291 (19.8)              807 (26.1) 
  
 
*Represents crisis-related admissions only. 
†Recurrent crises are those which required treatment with parenteral 
Opioid analgesics in the emergency room or during rehospitalization. 
Values in parentheses are percentages. Adapted from Ballas SK and Smith ED,
46
 Red Blood Cell 
Changes During the Evolution of the Sickle Cell Painful Crisis. Blood, 1992;79:2154-2163. 
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Table 3. Incidence of Hospital Readmissions for Acute Painful Episodes in 1998-2002 
        Hospital Readmissions after Discharge 
        Within 1 Week              Within 1 Month 
Patients, n 
    Males, n (%) 
    Females, n (%)  
     
    Total, n (%)                         
 
             27/55 (49)                           36/55(66) 
             28/62 (45)                           37/62 (60) 
 
             55/117 (47)                       73/117 (62) 
Readmissions 
    Males, n (%) 
    Females, n (%) 
     
    Total, n (%) 
 
             148/871 (17)                        516/871 (59) 
               80/586 (14)                        210/586 (36) 
   
             228/1457 (16)                      726/1457 (50) 
 
The numerator of each fraction represents the number of readmissions and the denominator 
represents the total number of hospital admissions before discharge. Values in parentheses are 
percentages. About 16% of readmissions occur one week after discharge and 50%  of 
readmissions occur after one month after discharge. Adapted from Ballas and Lusardi 43 with 
permission. 
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Table 4. Approaches to the Management of Sickle Cell Disease and its 
Complications 
 
Approach Definition 
1. Supportive Management Management intended to maintain the 
essential requirements for good health such 
balanced diet, sleep, hydration, folic acid, 
etc. 
2. Symptomatic Management Management targeted to alleviate the 
symptoms of the disease as they occur. 
These include blood transfusion for 
symptomatic anemia, analgesics for pain,  
antibiotics for infections, etc. 
3. Preventative management Approaches to prevent the occurrence of 
complications of the disease. These include 
things like vaccination, avoidance of 
stressful situations, Hb F induction with 
hydroxyurea or other agents, transfusion to 
prevent the recurrence of stroke, etc 
4. Abortive management Major purpose of this approach is to abort 
painful crisis thus preventing them from 
getting worse or precipitating other 
complication. The only promising abortive 
approach has been nitric oxide. 
5. Curative therapy This is the ultimate goal of all inherited 
disorders. This has already been achieved 
in SCD by stem cell transplantation. Gene 
therapy is another challenging goal. 
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Legends to Figures 
 
Figure 1. A typical profile of the events that develop during the evolution of a severe sickle 
cell painful crisis in an adult in the absence of overt infection or other complications. Such 
events are usually treated in the hospital with an average stay of 9-11 days. Pain becomes most 
severe by day 3 of the crisis and starts decreasing by day 6 or 7. The Roman numerals refer to 
the phase of the crisis: I, prodromal phase; II, initial phase; III, established phase; and IV, 
resolving phase. Dots on the X axis indicate the time when changes became apparent and dots on 
the Y axis indicate the relative value of change in comparison to the steady state indicated by the 
horizontal dashed line. Arrows indicate the time when certain clinical signs and symptoms may 
become apparent. Values shown are those reported at least twice by different investigators; 
values that were anecdotal, unconfirmed, or that were not reported to occur on a specific day of 
the crisis are not shown. Abbreviations: ISC, irreversibly sickled cells; RDW, red cell 
distribution width; HDW, hemoglobin distribution width; RBC DI, red cell deformability index; 
CRP, C-reactive protein; SAA, serum amyloid A; LDH, lactate dehydrogenase; CPK, creatinine 
phosphokinase; Hb, hemoglobin; ESR, erythrocyte sedimentation rate. Reproduced from Ballas 
SK. The sickle cell painful crisis in adults: phases and objective signs. Hemoglobin 48 1995; 
19:327; with permission. 
Figure 2. Two sequential painful crises with no pain during the time in between them. 
Figure 3. Pain intensity scores during hospitalization for acute painful episodes in 1998 –2002. 
 Adapted from Ballas & Lusardi 43 with permission. 
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Figure 4. Two sequential painful crises with residual pain during the time in between them. 
Severity of the residual pain between crises varies among patients and in the same patient with 
time as indicated by the arrows. 
Figure 5. Sequence of events during the evolution of the prodromal phase of the painful crisis. 
Tissue necrosis consequent to ischemia elicits an inflammatory response that is associated with 
an increase in the serum level of acute phase reactants. Adopted from Ballas. 90   
 
 
